Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.90 |
| ▸ | PPARD | Q03181 | 5/20 | 0.90 |
| ▸ | PPARA | Q07869 | 5/20 | 0.90 |
| ▸ | HTR6 | P50406 | 15/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR1E | P28566 | 1/20 | 0.61 |
| ▸ | HTR1F | P30939 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indeglitazar SCHEMBL3019199 | 0.95 | PPARG (1.00) | PPARGPPARDPPARAHTR6HTR1A | |
| Indeglitazar SCHEMBL29375502 | 0.95 | PPARG (1.00) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL4605850 | 0.92 | PPARG (0.94) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL14605552 | 0.92 | PPARG (0.90) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL4605145 | 0.92 | PPARG (0.94) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL3034510 | 0.91 | PPARG (0.89) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL3036864 | 0.91 | PPARG (0.88) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL5659494 | 0.91 | PPARG (0.88) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL3029862 | 0.91 | PPARG (0.88) | PPARGPPARDPPARAHTR6HTR1A | |
| SCHEMBL5662830 | 0.91 | PPARG (0.88) | PPARGPPARDPPARAHTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | claimed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | claimed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | claimed |
| US-7202266-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2007-04-10 | — | — | US | claimed |
| US-20050288354-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-12-29 | — | — | US | claimed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | claimed |
| EP-1648867-B1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC | 2012-01-19 | — | — | US | disclosed |
| US-8053463-B2 | e.g. {3-butoxy-5-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-phenyl}-acetic acid; peroxisome proliferator activated receptor modulator; antidiabetic agent; obesity, hyperlipidemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema | PLEXXIKON INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20060116416-A1 | PPAR active compounds | PLEXXIKON, INC | 2006-06-01 | — | — | US | disclosed |
| EP-1648867-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050288354-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005009958-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-5466689-A | Analgesics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0610793-A1 | Tetracyclic morpholine derivatives and their use or analgesics | Takeda Chemical Industries, Ltd. (JP) | 1994-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | PPARG 1/4885PPARD 2/4885PPARA 3/4885 |
| US-20050288354-A1 | PPAR active compounds | PPARG, PPARD, PPARA | PPARG 1/4885PPARD 2/4885PPARA 3/4885 |
| US-20060116416-A1 | PPAR active compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | PPARG 1/4885PPARD 2/4885PPARA 3/4885 |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | PPARG 1/4885PPARD 2/4885PPARA 3/4885 |
| US-20120015966-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.